Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 2, 2009, Pages 487-498

  Pautus, Stephane ^a   Aboraia, Ahmed S ^a   Bassett, Claire E ^a   Brancale, Andrea ^a   Coogan, Michael P ^b   Simons, Claire ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CYP26A1; Enzyme inhibition; IC50; Molecular modeling; N phenylbenzo d oxazolamines; Retinoic acid

Indexed keywords

ANILINE DERIVATIVE; BENZOOXAZOL 2 YL [PHENYL (IMIDAZOL 1 YLMETHYL)PHENYL]AMINE DERIVATIVE; CYTOCHROME P450 26A1; IMIDAZOLE DERIVATIVE; IMIDAZOLE N PHENYLBENZO[D]OXAZOLAMINE DERIVATIVE; ISOTHIOCYANIC ACID DERIVATIVE; LIAROZOLE; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; RETINOIC ACID; TETRAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TRIAZOLE N PHENYLBENZO[D]OXAZOLAMINE DERIVATIVE; UNCLASSIFIED DRUG; CYTOCHROME P450; ENZYME INHIBITOR; LIGAND; RETINOIC ACID 4 HYDROXYLASE; RETINOIC ACID 4-HYDROXYLASE;

ARTICLE; CYCLIZATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN DOMAIN; REACTION ANALYSIS; CHEMICAL STRUCTURE; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; LIGANDS; MODELS, MOLECULAR; SUBSTRATE SPECIFICITY; TRIAZOLES;

EID: 68049091987     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802218334     Document Type: Article

References (28)

1. Sporn MB, Roberts AB, Goodman DS, editors. The Retinoids, Biology, Chemistry and Medicine. New York: Academic Press; 1984. p 424.
2. SonneveldE,VandenBrinkCE,VanderLeede BJ,SchulkesRK, PetkovichM, Van der Burg B, Van der Saag PT.Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans- RA and can be induced through RA receptors in human breast and carcinoma cells. Cell Growth Differ 1998;9:629-637.
3. Ahmad N, Mukhtar H. Cytochrome P450: A target for drug development for skin diseases. J Investig Dermatol 2004;123: 417-425.
4. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003;49:171-182.
5. Estey EH, Giles F, Kantarjian H, O'Brien S, Cortes J, Freireich E, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukaemia. Blood 1999;94:2230-2235.
6. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, FeyM, Rayon C,Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, SanMiguel J, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. Blood 1999;94:1192-1200.
7. Guo WX, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995;55:823-829.
8. Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of alltrans- retinoic acid principal metabolites. Mol Pharmacol 2000;58:1341-1348.
9. Ray WJ, Bain G, Yao M, Gottlieb DI. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997;272:18702-18708.
10. GomaaMS, Yee SW,MilbourneCE, BarbaraM-C, Brancale A, Simons C. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): Active site architecture and ligand binding. J Enz Inhib Med Chem 2006; 21:361-369.
11. Kirby AJ, LeLain R, Mason P, Maharlouie F, Nicholls PJ, Smith HJ, Simons C. Inhibition of retinoic acid metabolising enzymes by 2-(4-aminophenylmethyl)- 6-hydroxy-3,4-dihydronaphthalen- 1(2H)-one and related compounds. J Enz Inhib Med Chem 2003;18:27-33.
12. Yee SW, Jarno L, GomaaMS, Elford C, Ooi L-L, CooganMP, McClelland R, NicholsonRI,EvansBAJ,BrancaleA, SimonsC. Novel tetralone-derived retinoic acid metabolism blocking agents: Synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays. J Med Chem 2005; 48: 7123-7131.
13. Pautus S, Yee SW, Jayne M, Coogan MP, Simons C. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4- alkyl/aryl)-methyl]-1H-triazoles. Bioorg Med Chem 2006;14: 3643-3653.
14. Gomaa MS, Bobillon B, Armstrong JL, Veal GJ, Brancale A, Redfern CPF, Simons C. Synthesis and in vitro evaluation of novel, 4-[(imidazol-1-yl and triazol-1-yl)(phenyl)methyl]arylamines: Potent CYP26 inhibitors and inducers of retinoic acid in Neuroblastoma cells. Bioorg Med Chem 2008; in press.
15. Njar VCO, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006;14:4323-4340.
16. Perrin DD, Armarengo WLF. Purification of Laboratory Chemicals. 3rd ed. New York: Pergamon Press; 1988.
17. Staskun B. Nuclear acylation of arylamides. J Org Chem 1964; 29:2856-2860.
18. Bridger GJ, Zhou Y, Skerlj R. Preparation of piperidines as chemokine receptor, particularly CCR5, modulators for the treatment of inflammatory and autoimmune disease. PCT Int Appl 2005; p. 384.
19. Massa S, Stefancich G, Corelli F, Silvestri R,Mai A, Artico M, Panico S, Simonetti N. Researches on antibacterial and antifungal agents. X. Synthesis and antifungal activities of 1-[ p-methyl-a-[4-(1H-pyrrol-1-yl)phenyl]benzyl]azoles and some related products. Archiv Pharm 1989;322:369-373.
20. Tripos SYBYL 7.0; Tripos Inc., 1699 South Hanley Rd, St. Louis, Missouri 63144, USA. http://www. tripos.com
21. Molecular Operating Environment (MOE). Chemical Computing Group, Inc. Montreal, Quebec, Canada: http://www. chemcomp.com.
22. Janssens F, Torremans J, Janssen M, Stokbroekx RA, Luyckx M, Janssen PAJ. New antihistaminic N-heterocyclic 4- piperidinamines. Synthesis and antihistaminic activity of N-(4-piperidinyl)-1H-benzimidazole-2-amines. J Med Chem 1985;28:1925-1933. (Pubitemid 16176852)
23. Aelterman W, Lang Y, Willemsens B, Vervest I, Leurs S, De Knaep F. Conversion of the laboratory synthetic route of the N-aryl-2-benzothiazolamine R116010 to a manufacturing method. Org Proc Res Dev 2001;5:467-471.
24. Vinh TK, Ahmadi M, Lopez Delgado PO, Fernandez Perez S, WaltersHM, SmithHJ, Nicholls PJ, SimonsC. 1-[(Benzofuran- 2-yl)-triazoles and -tetrazoles -potent competitive inhibitors of aromatase. BioorgMed Chem Lett 1999;9:2105-2108.
25. Lucker GPH, Heremans AMC, Boegheim PJ, Van de Kerkhof PCM, Steijlen PM. Oral treatment of ichthyosis by the cytochrome P450 inhibitor liarozole. Brit J Dermatol 1997; 136:71-75.
26. Denis L, Debruyne F, De Porre P, Bruynseels J. Early clinical experience with Liarozole (Liazal (TM)) in patients with progressive prostate cancer. Eur J Cancer 1998;34:469-475.
27. Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, Szel H, Van Hove C, Van Nyen G, Nobels G, Vanden Bossche H, Venet M, Willemsens G, Van Wauwe J. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodent. J Pharmacol Exp Ther 2000;293:304-312.
28. Saberi MR, Shah K, Simons C. Benzofuran- and furan-2-yl- (phenyl)-3-pyridylmethanols: Synthesis and inhibition of human placental aromatase (CYP19). J Enz Inhib Med Chem 2005;20:135-141.